James Downing to Step Down as St. Jude CEO After 12 Years of Historic Expansion
James R. Downing joined St. Jude Children's Research Hospital 40 years ago as a young scientist drawn to the opportunity to study childhood leukemia. He leaves the position of president and CEO having presided over the most significant physical, scientific, and global expansion in the institution's history - a period that included two strategic plans calling for investments totaling nearly $20 billion and the addition of more than 2,300 positions.
Downing announced in February 2026 that he will step down in late 2026 as part of a planned leadership transition. He will move into a faculty role in the Department of Global Pediatric Medicine, which he helped establish in 2018. The Board of Governors has launched a global search for the institution's next leader and expects to announce an incoming CEO this summer.
A Scientist Who Became a Builder
Downing's career at St. Jude began in 1986 as an assistant member in the Department of Pathology and Laboratory Medicine. His research focused on the genetic basis of childhood leukemia at a time when the underlying molecular drivers of pediatric cancer were poorly understood. Over the following two decades, he worked his way to department chair and then to scientific director in 2004.
In that scientific director role, he spearheaded the Pediatric Cancer Genome Project, a large-scale effort to map the genetic landscape of childhood cancers. That project generated data that shaped a new era of research and laid the groundwork for more targeted therapies in pediatric oncology. He was named president and CEO in 2014.
"When I joined St. Jude 40 years ago, I came for the opportunity to do great science, but I stayed because of the mission and culture," Downing said. "Nothing worth doing can be achieved in a single lifetime, nor can it be achieved alone. I'm merely a caretaker of St. Jude, and I look forward to helping the next leader fulfill our founder's dream that no child should die in the dawn of life."
What the Expansion Produced
The scale of what Downing oversaw is measurable in concrete terms. Major construction projects include The Domino's Village patient housing facility, the Inspiration4 Advanced Research Center, the St. Jude Data Center, and two new clinical towers opening next year. A second research center is under construction.
On the scientific side, his tenure included the establishment of St. Jude Cloud - described as the world's largest repository of pediatric cancer genomic data - along with new academic departments in imaging sciences, host-microbe interactions, cellular and molecular biology, and computational biology. St. Jude was also redesignated as an NCI Comprehensive Cancer Center and announced a cure for X-linked SCID, the condition commonly known as bubble boy disease.
The global program Downing helped build has become one of the hospital's most recognized contributions beyond clinical care. Under his leadership, St. Jude established its global alliance network, launched the Global Platform for Access to Childhood Cancer Medicines, and became the first World Health Organization collaborating center for childhood cancer - a designation that formalizes St. Jude's role as a resource for health systems in low- and middle-income countries where most of the world's childhood cancer deaths occur.
A Search With High Stakes
Judy Habib, chair of the St. Jude Board of Governors, credited Downing with making St. Jude a leader in the global movement to treat and cure children worldwide. The board will now conduct a search for a successor who can sustain the institution's momentum at a moment when the campus is mid-construction and the global mission is expanding.
Since St. Jude opened more than 60 years ago, treatments developed there have helped push the overall childhood cancer survival rate from 20% to 80%. Downing's faculty role in the Department of Global Pediatric Medicine will keep him connected to the international work he has championed throughout his tenure as CEO.